Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

NCT02268747 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Skin Squamous Cell Cancer

Interventions

DRUG: Dacomitinib

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano